Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,767 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PBRM1 and KDM5C cooperate to define high-angiogenesis tumors and increased antiangiogenic response in renal cancer.
Santos M, Lanillos J, Caleiras E, Valdivia C, Roldan-Romero JM, Laínez N, Puente J, Beuselinck B, Oudard S, Zucman-Rossi J, Navarro P, Robledo M, Castellano D, de Velasco G, García-Donas J, Rodriguez-Antona C. Santos M, et al. Am J Cancer Res. 2023 May 15;13(5):2116-2125. eCollection 2023. Am J Cancer Res. 2023. PMID: 37293154 Free PMC article.
PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
Roldan-Romero JM, Beuselinck B, Santos M, Rodriguez-Moreno JF, Lanillos J, Calsina B, Gutierrez A, Tang K, Lainez N, Puente J, Castellano D, Esteban E, Climent MA, Arranz JA, Albersen M, Oudard S, Couchy G, Caleiras E, Montero-Conde C, Cascón A, Robledo M, Rodríguez-Antona C, García-Donas J; Spanish Oncology Genitourinary Group (SOGUG). Roldan-Romero JM, et al. Among authors: santos m. Int J Cancer. 2020 Mar 1;146(5):1435-1444. doi: 10.1002/ijc.32579. Epub 2019 Aug 9. Int J Cancer. 2020. PMID: 31335987
Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.
Roldan-Romero JM, Santos M, Lanillos J, Caleiras E, Anguera G, Maroto P, García-Donas J, de Velasco G, Martinez-Montes ÁM, Calsina B, Monteagudo M, Letón R, Leandro-García LJ, Montero-Conde C, Cascón A, Robledo M, Rodriguez-Antona C. Roldan-Romero JM, et al. Among authors: santos m. Mod Pathol. 2020 Dec;33(12):2580-2590. doi: 10.1038/s41379-020-0607-z. Epub 2020 Jul 2. Mod Pathol. 2020. PMID: 32616874 Free article.
Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma.
Santos M, Lanillos J, Roldan-Romero JM, Caleiras E, Montero-Conde C, Cascón A, Climent MA, Anguera G, Hernando S, Laínez N, Robledo M, Robles L, de Velasco G, García-Donas J, Rodriguez-Antona C. Santos M, et al. Genet Med. 2021 Apr;23(4):698-704. doi: 10.1038/s41436-020-01062-0. Epub 2021 Jan 13. Genet Med. 2021. PMID: 33442023 Free article.
Interrogating the Significance of PARP1 Expression and PBRM1 Mutation as Biomarkers for Predicting the Response to Atezolizumab plus Bevacizumab or to Sunitinib in Patients with Clear Cell Renal Cell Carcinoma.
Lanillos J, Santos M, Valdivia C, Mora A, Rodríguez-Antona C. Lanillos J, et al. Among authors: santos m. Eur Urol. 2022 Sep;82(3):334-335. doi: 10.1016/j.eururo.2022.05.013. Epub 2022 Jun 7. Eur Urol. 2022. PMID: 35688666 No abstract available.
Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition.
Roldán-Romero JM, Valdivia C, Santos M, Lanillos J, Maroto P, Anguera G, Calsina B, Martinez-Montes A, Monteagudo M, Mellid S, Leandro-García LJ, Montero-Conde C, Cascón A, Roncador G, Coloma J, Robledo M, Rodriguez-Antona C. Roldán-Romero JM, et al. Among authors: santos m. Int J Cancer. 2023 Sep 15;153(6):1300-1312. doi: 10.1002/ijc.34575. Epub 2023 Jun 1. Int J Cancer. 2023. PMID: 37260183
Hsa-miR-139-5p is a prognostic thyroid cancer marker involved in HNRNPF-mediated alternative splicing.
Montero-Conde C, Graña-Castro O, Martín-Serrano G, Martínez-Montes ÁM, Zarzuela E, Muñoz J, Torres-Perez R, Pita G, Cordero-Barreal A, Leandro-García LJ, Letón R, López de Silanes I, Guadalix S, Pérez-Barrios A, Hawkins F, Guerrero-Álvarez A, Álvarez-Escolá C, Regojo-Zapata RM, Calsina B, Remacha L, Roldán-Romero JM, Santos M, Lanillos J, Jordá M, Riesco-Eizaguirre G, Zafon C, González-Neira A, Blasco MA, Al-Shahrour F, Rodríguez-Antona C, Cascón A, Robledo M. Montero-Conde C, et al. Among authors: santos m. Int J Cancer. 2020 Jan 15;146(2):521-530. doi: 10.1002/ijc.32622. Epub 2019 Aug 28. Int J Cancer. 2020. PMID: 31403184
DLST mutations in pheochromocytoma and paraganglioma cause proteome hyposuccinylation and metabolic remodeling.
Mellid S, García F, Leandro-García LJ, Díaz-Talavera A, Martínez-Montes ÁM, Gil E, Calsina B, Monteagudo M, Letón R, Roldán-Romero JM, Santos M, Lanillos J, Valdivia C, Martínez-Puente N, de Nicolás-Hernández J, Jiménez S, Pérez-Martínez M, Honrado E, Coloma J, Cerezo A, Santiveri CM, Esteller M, Campos-Olivas R, Caleiras E, Montero-Conde C, Rodríguez-Antona C, Muñoz J, Robledo M, Cascón A. Mellid S, et al. Among authors: santos m. Cancer Commun (Lond). 2023 Jul;43(7):838-843. doi: 10.1002/cac2.12427. Epub 2023 May 4. Cancer Commun (Lond). 2023. PMID: 37139660 Free PMC article. No abstract available.
CD133 Expression in Medullary Thyroid Cancer Cells Identifies Patients with Poor Prognosis.
Cordero-Barreal A, Caleiras E, López de Maturana E, Monteagudo M, Martínez-Montes ÁM, Letón R, Gil E, Álvarez-Escolá C, Regojo RM, Andía V, Marazuela M, Guadalix S, Calatayud M, Robles-Díaz L, Aguirre M, Cano JM, Díaz JÁ, Saavedra P, Lamas C, Azriel S, Sastre J, Aller J, Leandro-García LJ, Calsina B, Roldán-Romero JM, Santos M, Lanillos J, Cascón A, Rodríguez-Antona C, Robledo M, Montero-Conde C. Cordero-Barreal A, et al. Among authors: santos m. J Clin Endocrinol Metab. 2020 Nov 1;105(11):dgaa527. doi: 10.1210/clinem/dgaa527. J Clin Endocrinol Metab. 2020. PMID: 32791518
10,767 results
You have reached the last available page of results. Please see the User Guide for more information.